What is NDC 31722-001?

31722-001 is the product NDC for lamivudine, Lamivudine 100 mg/1 tablet, film coated, listed with the FDA by Camber Pharmaceuticals, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Camber Pharmaceuticals, Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for lamivudine?

24 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

lamivudine NDC 31722-001 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
31722-001-02	31722000102	20 BLISTER PACK in 1 CARTON (31722-001-02) / 10 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Mar 21, 2019
31722-001-60	31722000160	60 TABLET, FILM COATED in 1 BOTTLE (31722-001-60)Marketed from Mar 21, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 100 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Camber Pharmaceuticals, Inc.NDC labeler code 31722
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211306
Marketing start: Mar 21, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 31722-001_2b449c4a-56db-0d5f-e063-6394a90ad576SPL ID 2b449c4a-56db-0d5f-e063-6394a90ad576SPL set ID e90671c6-7fff-48f4-8898-29f02d049c8bRxCUI 205328UNII 2T8Q726O95UPC 0331722001601
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722000102 followed by a unit qualifier and the quantity

Package 31722-0001-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 9, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with HIV, hepatitis C virus…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 31722-001

What is NDC 31722-001?: 31722-001 is the product NDC for lamivudine, Lamivudine 100 mg/1 tablet, film coated, listed with the FDA by Camber Pharmaceuticals, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: lamivudine.
What is the active ingredient?: Lamivudine.
Who is the labeler?: Camber Pharmaceuticals, Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for lamivudine?: 24 other product NDCs are listed under this name. See all lamivudine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other lamivudine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-1459	67046-1459-03
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	American Health Packaging	60687-720	60687-0720-21
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-001	33342-0001-09
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-002	33342-0002-07
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-710	64380-0710-03
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-711	64380-0711-04
Lamivudine	Lamivudine 150 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-623	50742-0623-60
Lamivudine	Lamivudine 300 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-624	50742-0624-60
Lamivudine	Lamivudine 10 mg/mL	SolutionOral	Rising Pharma Holdings, Inc.	57237-274	57237-0274-24
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	65862-025	65862-0025-1065862-0025-60

All 25 lamivudine NDCs